Therapy News and Research

RSS

New clinical trial to evaluate effectiveness of ABMT for PTSD

At Ease USA, a Nebraska organization dedicated to providing confidential post-traumatic stress disorder (PTSD) care for military families, has launched a clinical trial of a promising new therapeutic intervention at Creighton University.

14 May 2012

DIBH can spare hearts and lungs of breast cancer patients from radiation

Respiratory movement during radiotherapy makes it difficult to hit the right treatment target and this in turn can lead to an under-dose of radiation to the tumour, or a potentially toxic over-dose to the surrounding healthy tissue. Getting this right is a real challenge for the radiotherapist, but new techniques are helping to deliver the correct dose to the right place, the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO 31) will hear today.

14 May 2012

Kidney transplants more frequent among NxStage home hemodialysis patients

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today commented on findings of the Chronic Disease Research Group (CDRG) study showing that patients receiving daily, or more frequent, home hemodialysis with the NxStage System One are more likely to receive a kidney transplant when compared with conventional thrice-weekly dialysis, particularly in patients not on the transplant waitlist at initiation of daily home hemodialysis.

14 May 2012

Lenalidomide delays progression of multiple myeloma after stem cell transplant

Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called autologous hematopoietic stem cell transplantation, commonly known as a stem cell transplant, is frequently an important treatment option for many patients.

14 May 2012

New mom receives surprise heart transplant

New mom Windy Hill, 38, of Kingsport, Tenn., was given the ultimate Mother's Day gift a little early after she was wheeled into the operating room at Vanderbilt University Hospital on April 20 to receive a mechanical pump to aid her failing heart and save her life.

14 May 2012

Regenerating sensory hair cells could help treat hearing loss

Regenerating sensory hair cells, which produce electrical signals in response to vibrations within the inner ear, could form the basis for treating age- or trauma-related hearing loss. One way to do this could be with gene therapy that drives new sensory hair cells to grow.

14 May 2012

Researchers uncover new way to stimulate activity of immune cell opiate receptors

Researchers at Rutgers University have uncovered a new way to stimulate activity of immune cell opiate receptors, leading to efficient tumor cell clearance.

14 May 2012

CRT-D cost-effective treatment for mildly symptomatic heart failure patients

Medtronic, Inc. today announced findings from an economic analysis of the landmark RAFT (Resynchronization / Defibrillation in Ambulatory Heart Failure Trial) trial demonstrating that cardiac resynchronization therapy with defibrillation (CRT-D) is a cost-effective treatment for mildly symptomatic heart failure patients.

14 May 2012

FDA ADAC recommends approval of Quad for HIV-1 infection

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 1 in support of approval of the Quad, a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, for the treatment of HIV-1 infection in treatment-naïve adults.

14 May 2012

Lung cancer molecular subtypes correlate with genetic alterations, patient's response to therapy

Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient's individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient's response to therapy.

14 May 2012

Novel heart monitoring device helps ER patients avoid unnecessary follow-up care

A study conducted at Scripps Health has found that a novel new heart monitoring device helped emergency room patients avoid unnecessary follow-up care. Scripps Health electrophysiologist Steven Higgins, MD, presented findings of the study titled, "Prevalence of Arrhythmias in Emergency Department Patients Discharged Using a Novel Ambulatory Cardiac Monitor", today at the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston.

14 May 2012

Women more likely to suffer PTSD after being discharged from ICU

Women are more likely to suffer post-traumatic stress than men after leaving an intensive care unit (ICU), finds a new study published in BioMed Central's open access journal Critical Care. However, psychological and physical 'follow-up' can reduce both this and post-ICU depression.

14 May 2012

NBHA commends FDA for continuing investigation of bisphosphonate treatment for osteoporosis

In response to today's Perspective pieces published in the New England Journal Of Medicine, the National Bone Health Alliance (NBHA), a public-private partnership bringing together the expertise and resources of its 42 members from the private and non-profit sectors to collectively advance bone health and prevent disease, commends the U.S. Food and Drug Administration (FDA) for continuing to investigate the risks and benefits of long-term bisphosphonate treatment.

11 May 2012

FDA warns about 'liberation therapy' for multiple sclerosis

The U.S. Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called "liberation therapy" or the "liberation procedure" to treat chronic cerebrospinal venous insufficiency (CCSVI).

11 May 2012

BioTrends tracks uptake of Yervoy and Zelboraf for advanced melanoma

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the second wave of its LaunchTrends® Yervoy and Zelboraf report, in which 103 U.S.-based medical oncologists were surveyed about their current and expected treatment patterns in advanced melanoma.

11 May 2012

Threshold for when to choose surgery over medical therapy for recurrent acute rhinosinusitis

A study in the May 2012 issue of Otolaryngology-Head and Neck Surgery suggests a threshold for when to choose surgery over medical therapy for recurrent acute rhinosinusitis (RARS) based on the patients' lost productivity in response to RARS and each treatment strategy.

11 May 2012

Positive results from Cytochroma CTAP101 Phase 2b clinical trial for CKD

Cytochroma today announced positive clinical trial results for its lead product, CTAP101 Capsules. In a recently completed Phase 2b trial, CTAP101 Capsules effectively and safely lowered elevated plasma intact parathyroid hormone (iPTH) in patients with Stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

11 May 2012

Study supports catheter ablation as first-line treatment for paroxysmal atrial fibrillation

Patients with the heart rhythm disorder atrial fibrillation (AFib) who received first-line catheter ablation treatment had a longer arrhythmia-free interval than patients receiving antiarrhythmic drugs, the standard first-line treatment.

11 May 2012

BIOTRONIK launches new Reocor external pacemaker

BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK's portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.

11 May 2012

Two types of stent systems are both effective in treating iliac artery disease

Two types of stent systems are both effective in treating patients who have severe forms of peripheral artery disease (PAD), according to results of the MOBILITY trial presented today as a late-breaking clinical trial at the SCAI 2012 Scientific Sessions.

11 May 2012